The best move has been to simply stick with the trend.
The markets' focus will be on the pace of future interest rate hikes.
Some small names are interesting, but more-aggressive position trades are not developing right now.
Why the name is sagging, and what it will take to spur the sector higher.
This stock is testing resistance and could push back up to last year's highs.
The firms all have drugs they want the feds to bend the rules to approve.
Traders should look to go long on a close above $84.
Companies developing drugs for cancer, eye problems and pets -- offer untapped value.
The S&P 500 is hitting intraday lows, and I'm watching whether the market can rally again this afternoon.
Akorn and AmerisourceBergen are both flashing big moves, but in which direction is unclear.

Columnist Conversations

SPX weekly View Chart »  View in New Window » $SPX Daily


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.